New phase 1 entrants include Claudin18.2-targeting ADCs from Astra and Bolt.
ApexOnco Front Page
Recent articles
Three off-the-shelf mRNA therapies join intismeran autogene.
Safusidenib could eclipse the recently approved brain cancer drug, Nuvation claims.
The Japanese group licenses sapablursen from Ionis for $280m.
The companies press on with vilastobart and IMPT-314... up to a point.
Recent first-in-human trials include Pheast and Auron, plus new targets from Immunocore and Cero.
The Pfizer-partnered vepdegestrant shows a benefit in ESR1 mutants, but not in all-comers.
J&J decides not to opt in to erzotabart, and Genmab pulls the plug.
